仑伐替尼联合帕博利珠单抗对比舒尼替尼一线治疗晚期肾细胞癌:CLEAR III期研究最终预设总生存分析
CLEAR是一项开放标签III期研究,在未经治疗的晚期肾细胞癌患者中比较仑伐替尼联合帕博利珠单抗与舒尼替尼。最终预设总生存分析显示,联合组总生存风险比(HR)为0.79(95%CI 0.63至0.99),中位总生存53.7个月对比54.3个月,36个月总生存率分别为66.4%和60.2%。
要点
- 联合组总生存HR为0.79(95%CI 0.63至0.99),中位总生存53.7个月对比舒尼替尼54.3个月。
- 联合组中位无进展生存23.9个月对比舒尼替尼9.2个月,HR为0.47(95%CI 0.38至0.57)。
- 联合组客观缓解率71.3%对比舒尼替尼36.7%,相对风险1.94(95%CI 1.67至2.26)。
核心结论
- 在未经治疗的晚期肾细胞癌患者中,仑伐替尼联合帕博利珠单抗取得了与舒尼替尼相比一致且持久的获益,安全性可控。
研究设计与样本
- 开放标签III期CLEAR研究,未经治疗的晚期肾细胞癌患者随机接受仑伐替尼联合帕博利珠单抗或舒尼替尼治疗,本次为最终预设总生存分析,数据截止日期为2022年7月31日。
主要发现
- 仑伐替尼联合帕博利珠单抗组总生存HR为0.79(95%CI 0.63至0.99);中位总生存53.7个月(95%CI 48.7至不可估计)对比舒尼替尼组54.3个月(95%CI 40.9至不可估计)。
- 仑伐替尼联合帕博利珠单抗组36个月总生存率为66.4%(95%CI 61.1至71.2),舒尼替尼组为60.2%(95%CI 54.6至65.2)。
- 仑伐替尼联合帕博利珠单抗组中位无进展生存为23.9个月(95%CI 20.8至27.7),舒尼替尼组为9.2个月(95%CI 6.0至11.0),HR为0.47(95%CI 0.38至0.57)。
- 仑伐替尼联合帕博利珠单抗组客观缓解率为71.3%,舒尼替尼组为36.7%,相对风险1.94(95%CI 1.67至2.26)。
- 接受任一治疗的患者中,治疗中出现的不良事件发生率均超过90%。
关键数值与推荐
- 仑伐替尼联合帕博利珠单抗方案:仑伐替尼20 mg口服每日一次,21天为一周期;帕博利珠单抗200 mg静脉注射每3周一次。
- 舒尼替尼方案:50 mg口服每日一次,用药4周停药2周。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical trial updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.We present the final prespecified overall survival (OS) analysis of the open-label, phase III CLEAR study in treatment-naïve patients with advanced renal cell carcinoma (aRCC). With an additional follow-up of 23 months from the primary analysis, we report results from the lenvatinib plus pembrolizumab versus sunitinib comparison of CLEAR. Treatment-naïve patients with aRCC were randomly assigned to receive lenvatinib (20 mg orally once daily in 21-day cycles) plus pembrolizumab (200 mg intravenously once every 3 weeks) or sunitinib (50 mg orally once daily [4 weeks on/2 weeks off]). At this data cutoff date (July 31, 2022), the OS hazard ratio (HR) was 0.79 (95% CI, 0.63 to 0.99). The median OS (95% CI) was 53.7 months (95% CI, 48.7 to not estimable [NE]) with lenvatinib plus pembrolizumab versus 54.3 months (95% CI, 40.9 to NE) with sunitinib; 36-month OS rates (95% CI) were 66.4% (95% CI, 61.1 to 71.2) and 60.2% (95% CI, 54.6 to 65.2), respectively. The median progression-free survival (95% CI) was 23.9 months (95% CI, 20.8 to 27.7) with lenvatinib plus pembrolizumab and 9.2 months (95% CI, 6.0 to 11.0) with sunitinib (HR, 0.47 [95% CI, 0.38 to 0.57]). Objective response rate also favored the combination over sunitinib (71.3% v 36.7%; relative risk 1.94 [95% CI, 1.67 to 2.26]). Treatment-emergent adverse events occurred in >90% of patients who received either treatment. In conclusion, lenvatinib plus pembrolizumab achieved consistent, durable benefit with a manageable safety profile in treatment-naïve patients with aRCC.
引用
- Motzer RJ, Porta C, Eto M, et al. Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study. J Clin Oncol. 2024. PMID: 38227898. doi:10.1200/JCO.23.01569
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。